ストックスクリーナーアプリを入手
1.51
7.62%
-0.13
アフターアワーズ：
1.53
0.02
+1.32%
前日終値:
$1.64
開ける：
$1.61
24時間の取引高:
1.11M
Relative Volume:
1.77
時価総額：
$2.22M
収益：
$502.40K
当期純損益:
$-7.91M
株価収益率:
-0.1514
EPS:
-9.972
ネットキャッシュフロー:
$-4.32M
1週間 パフォーマンス:
-41.95%
1か月 パフォーマンス:
-26.81%
6か月 パフォーマンス:
-63.41%
1年 パフォーマンス:
-89.20%
1日の値動き範囲:
$1.50
$1.63
1週間の範囲:
$1.50
$2.64
52週間の値動き範囲:
$1.41
$35.99
60 Degrees Pharmaceuticals Inc Stock (SXTP) Company Profile
名前
60 Degrees Pharmaceuticals Inc
セクター
電話
202-327-5422
住所
1025 CONNECTICUT AVENUE NW, WASHINGTON
SXTP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SXTP
60 Degrees Pharmaceuticals Inc
|
1.51 | 3.62M | 502.40K | -7.91M | -4.32M | -9.972 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
60 Degrees Pharmaceuticals Inc (SXTP) 最新ニュース
60 Degrees Pharmaceuticals to study tafenoquine against Lyme disease By Investing.com - Investing.com India
60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria - The Manila Times
60 Degrees Pharmaceuticals to study tafenoquine against Lyme disease - Investing.com
Major Breakthrough: Anti-Malaria Drug Tafenoquine Being Tested for Lyme Disease Treatment - Stock Titan
60 Degrees Pharmaceuticals' Warrant Gambit: Balancing Liquidity and Longevity - AInvest
60 Degrees Pharmaceuticals closes $5 million public offering By Investing.com - Investing.com South Africa
60 Degrees Pharmaceuticals closes $5 million public offering - Investing.com Australia
60 Degrees Pharmaceuticals Secures $5 Million in Public Offering - AInvest
60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering - Yahoo Finance
Form 424B4 60 DEGREES PHARMACEUTICA - StreetInsider
Trade Desk Shares Surge 15% Amid S&P 500 Inclusion - AInvest
Why 60 Degrees Pharmaceuticals Inc. Equity Warrant stock attracts strong analyst attentionProfitable Yet Secure Picks - Newser
60 Degrees Pharmaceuticals Prices $10 Million Public Offering - citybiz
How 60 Degrees Pharmaceuticals Inc. stock performs during market volatilityFree Stock Market Real-Time Monitoring - Newser
SXTP Crashes 21%—What’s Behind the Unraveling of 60 Degrees Pharma? - AInvest
SXTP Stock’s Upward Trend: What Lies Ahead? - StocksToTrade
60 Degrees Pharmaceuticals' $10M Raise: A High-Risk Gamble on Capital Efficiency? - AInvest
60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering - The Manila Times
What makes 60 Degrees Pharmaceuticals Inc. stock price move sharplyFree Step-by-Step Investment Guide - Newser
60 Degrees Pharmaceuticals Secures Up to $10M Funding: New Capital Injection for Infectious Disease Breakthroughs - Stock Titan
Why 60 Degrees Pharmaceuticals Inc. stock attracts strong analyst attentionFree Stock Investment Discussion Area - Newser
What makes Recursion Pharmaceuticals Inc. stock price move sharplyFree Smart Investment Opportunities - Newser
Why BridgeBio Pharma Inc. stock attracts strong analyst attentionFree Professional Portfolio Management - Newser
60 Degrees Pharma targets $245 million market for babesiosis treatment - Investing.com Australia
60 Degrees Pharma targets $245 million market for babesiosis treatment By Investing.com - Investing.com South Africa
Major FDA Development: Pierre Fabre Assumes Control of Atara's EBV Cell Therapy Program After BLA Resubmission - Stock Titan
Why Trade Desk Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Benzinga
60 Degrees Pharmaceuticals Inc (SXTP) Stock Soars 77.83% on MUMS Designation Plans - AInvest
Breakthrough Babesiosis Drug ARAKODA Targets $1.1B Market Opportunity, FDA Filing Next Year - Stock Titan
How 60 Degrees Pharmaceuticals Inc. Equity Warrant stock performs during market volatilityWeekly Big Movers - Newser
60 Degrees Pharmaceuticals’ (SXTP) Sell (E+) Rating Reiterated at Weiss Ratings - Defense World
Sypris Solutions (NASDAQ:SYPR) vs. IES (NASDAQ:IESC) Head-To-Head Analysis - Defense World
Reviewing International Flavors & Fragrances (NYSE:IFF) and H. B. Fuller (NYSE:FUL) - Defense World
New Semiconductor SPAC Launches $100M IPO: Silver Pegasus Targets Tech Acquisitions - Stock Titan
60 Degrees Pharmaceuticals: Leveraging MUMS Designation to Tackle Canine Babesiosis and Drive Growth - AInvest
60 Degrees to Submit FDA MUMS Request for Tafenoquine in Canine Babesiosis - MarketScreener
60 Degrees Pharmaceuticals stock surges on canine babesiosis treatment plans - Investing.com
First FDA-Approved Oral Treatment for Dangerous Tick-Borne Dog Disease Could Be Coming in 2025 - Stock Titan
Biotech Giant Vertex Pharmaceuticals Schedules Q2 2025 Earnings CallKey Details for Investors - Stock Titan
Trinity Capital Sets Q2 2025 Earnings Call: Live Webcast and Phone Access Available - Stock Titan
Breakthrough Brain Cancer Drug REYOBIQ Achieves 80% Tumor Reduction in Phase 1 Trial, Advances to Next Stage - Stock Titan
Eupraxia's Revolutionary EoE Drug Enters Critical Phase 2b Trial: Direct Injection Method Shows Promise - Stock Titan
Eton's New Pediatric Drug Solution Advances Toward FDA Approval, Targeting $1B Market Opportunity - Stock Titan
GAMMA Investing LLC Grows Stock Position in M/I Homes, Inc. (NYSE:MHO) - Defense World
FDA Breakthrough: First-Ever Oral Drug for HAE Attacks Ends Decade of Injectable-Only Treatments - Stock Titan
Prudential Financial Sets Q2 Earnings Date: $1.5T Asset Manager Reports July 30 - Stock Titan
Prospect Capital Expands Consumer Credit Portfolio with Strategic $115M QC Holdings Buyout - Stock Titan
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given “Sell (E+)” Rating at Weiss Ratings - Defense World
Xenon Makes Major League Move: Dual Russell Index Inclusion Opens Door to $10.6T Investment Pool - Stock Titan
Major Breakthrough: Corvus Expands Atopic Dermatitis Drug Development into Chinese Market with New Trial Approval - Stock Titan
First Patient Shows Zero Toxicity in CERo's Groundbreaking Cancer Immunotherapy Trial - Stock Titan
60 Degrees Pharmaceuticals Inc (SXTP) 財務データ
収益
当期純利益
現金流量
EPS
60 Degrees Pharmaceuticals Inc (SXTP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| XU CHERYL | Director |
Dec 13 '24 |
Buy |
1.56 |
6,000 |
9,375 |
52,078 |
| XU CHERYL | Director |
Dec 12 '24 |
Buy |
1.82 |
5,000 |
9,125 |
46,078 |
| XU CHERYL | Director |
Dec 16 '24 |
Buy |
1.45 |
2,000 |
2,900 |
54,078 |
| DOW GEOFFREY S | President and CEO |
Dec 09 '24 |
Buy |
1.27 |
35,823 |
45,563 |
94,580 |
| DOW GEOFFREY S | President and CEO |
Dec 06 '24 |
Buy |
1.20 |
20,579 |
24,672 |
58,757 |
| DOW GEOFFREY S | President and CEO |
Dec 05 '24 |
Buy |
1.11 |
17,549 |
19,520 |
38,178 |
| DOW GEOFFREY S | President and CEO |
Nov 21 '24 |
Buy |
0.91 |
3,500 |
3,195 |
20,629 |
| DOW GEOFFREY S | President and CEO |
Nov 19 '24 |
Buy |
0.90 |
2,500 |
2,248 |
16,129 |
| DOW GEOFFREY S | President and CEO |
Nov 20 '24 |
Buy |
0.92 |
1,000 |
924 |
17,129 |
| XU CHERYL | Director |
Aug 27 '24 |
Buy |
1.70 |
5,000 |
8,500 |
41,078 |
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):